Patents by Inventor Arvin YANG

Arvin YANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220135685
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: November 10, 2021
    Publication date: May 5, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Publication number: 20200010549
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: June 3, 2019
    Publication date: January 9, 2020
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Publication number: 20190194328
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: January 4, 2019
    Publication date: June 27, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Patent number: 10174113
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 8, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventor: Arvin Yang
  • Publication number: 20160362489
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: April 28, 2016
    Publication date: December 15, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG
  • Publication number: 20160340428
    Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 24, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventor: Arvin YANG